

## Baloxavir vs Standard treatment for COVID-19

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Baloxavir vs Standard treatment be used for COVID-19?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Baloxavir	Standard treatment	Relative (95% CI)	Absolute (95% CI)	
<b>SARS-CoV-2 clearance</b>											
1 <sup>1,a</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	very serious <sup>c</sup>	none	7/10 (70.0%)	10/10 (100.0%)	<b>RR 0.71</b> (0.47 to 1.09)	<b>290 fewer per 1.000</b> (from 530 fewer to 90 more)	⊕○○○ VERY LOW
<b>Number of patients with respiratory failure and respiratory distress syndrome</b>											
1 <sup>1</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	serious <sup>d</sup>	none	4/9 (44.4%)	4/10 (40.0%)	<b>RR 1.11</b> (0.39 to 3.19)	<b>44 more per 1.000</b> (from 244 fewer to 876 more)	⊕○○○ VERY LOW
<b>Mortality any cause</b>											
1 <sup>1</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	serious <sup>d</sup>	none					⊕○○○ VERY LOW

**CI:** Confidence interval; **RR:** Risk ratio

### Explanations

a. Both groups receive standard treatment involving Lopinavir / Ritonavir or darunavir / cobicistat and umifenovir, in combination with interferon  $\alpha$

b. Downgraded of two levels for high risk of performance bias and unclear risk of selection bias and reporting bias

c. Downgraded of two levels for very low number of events and small sample size

d. Downgraded of one level for small sample size

### References

1. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. medRxiv doi: <https://doi.org/10.1101/2020.04.29.20085761>